Nancy
Updates on the planned allocation of the cash raised from the 2018 fundraising
1. Date of the board of directors resolution for the change: May 7, 2021 2. Effective registration date of the original plan: Mar 25, 2019 3. Major change Reason for …
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study
1. Date of occurrence of the event: May 6, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned
1. Date of occurrence of the event: May 5, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company’s Board of Directors resolved to convene the 2021 Annual General Shareholders’ Meeting
1. Date of the board of directors’ resolution: April 29, 2021 2. General shareholders’ meeting date: June 15, 2021 3. General shareholders’ meeting location: 5th Floor, No.19, Shengyi 5th Rd., …
Announcement of the resolution by the Board of Directors not to distribute dividends by the company, on behalf of major subsidiary Amaran Biotechnology, Inc.
1. Date of the board of directors’ resolution: April 29, 2021 2. Type and monetary amount of dividend distribution: N/A 3. Any other matters that need to be specified: None
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL
First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, in T-Cell Acute Lymphocytic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) TAIPEI, Taiwan, …
OBI-3424 completes its phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to phase 2 as planned
1. Date of occurrence of the event: April 21, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI Filed the Application of Phase III Human Clinical Study for the Active Cancer Immunotherapy OBI-822, Adagloxad Simolenin, to the Health Authority of Peru
1. Date of occurrence of the event: Apr 20, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4
Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 Poster Number: 1220 / Abstract number: 1062 Title: Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998 Poster number: …
OBI’s application to initiate the Phase III clinical study of the active cancer immunotherapy OBI-822 (Adagloxad Simolenin) has been denied by the Ministry of Health, Argentina
1. Date of occurrence of the event: Apr 7, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …